Filing search / Iovance Biotherapeutics, Inc. / "Department of" / Page 4

8-K

EX-99.1

xvyzyj9 hcq6

3 Jun 19

June 2019 © 2019, Iovance Biotherapeutics, Inc. Corporate Presentation

4:30pm

8-K

EX-10.1

7d5gx6

3 Jun 19

June 2019 © 2019, Iovance Biotherapeutics, Inc. Corporate Presentation

4:30pm

8-K

EX-99.2

suosxbbtnfvbh

16 May 19

Iovance Biotherapeutics Announces Updates to Tumor Infiltrating Lymphocyte (TIL) Therapy Clinical Programs

5:20pm

8-K

EX-99.1

ybwaje9d44cqphm6c

7 Jan 19

Results of Operations and Financial Condition

8:30am

8-K

EX-10.1

v5whsk

25 Oct 18

Entry into a Material Definitive Agreement

4:45pm

8-K

EX-99.1

r3wfw5iifm9b 7ee

17 Oct 18

Iovance Biotherapeutics, Inc. Announces Closing of $252 Million Common Stock Public Offering

7:02am

8-K

EX-99.1

jvx3t7 rce9

12 Oct 18

Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock

4:06pm

8-K

EX-99.2

9clc fozglgcywjp

12 Oct 18

Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock

4:06pm

8-K

EX-1.1

ewkd 2extm4

12 Oct 18

Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock

4:06pm